IMG-20260527-WA0035.jpg
IMG-20260527-WA0036.jpg
Explain
Reading File
These notes cover Novel Antimicrobials - specifically drugs that overcome beta-lactamase resistance. Let me look up the library content and analyze both images in parallel.
analyse_media
analyse_media
Finding Sources
Finding Sources
Now I have a clear picture of the notes. Let me search the library for specific drug content in parallel.
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Now let me read the key textbook sections for ceftazidime-avibactam and lipoglycopeptides for more depth.
Reading File
Reading File
Reading File
I now have all the information needed for a comprehensive explanation. Here is the full breakdown of everything in your notes:
Newer / Novel Antimicrobials
Your notes are organized into 7 categories of newer antimicrobial agents. Here is a full explanation of each:
① Beta-Lactam Antibiotic + Beta-Lactamase Inhibitors
Core concept: Beta-lactamase enzymes are the main resistance mechanism bacteria use to destroy beta-lactam antibiotics. These newer combinations pair a beta-lactam with a novel beta-lactamase inhibitor that protects the antibiotic from destruction.
Cephalosporin + Inhibitor Combinations
| Combination | Generation | Key Inhibitor | Clinical Use |
|---|---|---|---|
| Ceftazidime + Avibactam | 3rd gen | Avibactam (Class A, C, D coverage) | MDR Gram-negatives, ESBL, KPC, P. aeruginosa |
| Ceftolozane + Tazobactam | 3rd gen | Tazobactam | MDR P. aeruginosa, resistant Enterobacterales |
Avibactam is a non-beta-lactam inhibitor that covers Class A (KPC, TEM, SHV, CTX-M), Class C (AmpC), and some Class D (OXA) beta-lactamases - but NOT Class B (metallo-beta-lactamases/MBLs). Both are IV only and reserved for multidrug-resistant infections including complicated UTIs and intra-abdominal infections (with metronidazole). - Lippincott Illustrated Reviews Pharmacology, p. 968
Carbapenem + Inhibitor Combinations
| Combination | Key Inhibitor | Notes |
|---|---|---|
| Meropenem + Vaborbactam | Vaborbactam (boronic acid structure) | Active against KPC-producing CRE; approved for complicated UTIs |
| Imipenem + Relebactam | Relebactam (structurally similar to avibactam) | Also approved for hospital-acquired and ventilator-associated pneumonia |
These combinations target carbapenem-resistant Enterobacteriaceae (CRE) - one of the most serious resistant organisms. - Lippincott Illustrated Reviews Pharmacology, p. 969
4th Generation Cephalosporins
These are listed as a group in your notes:
- Cefepime - widely used 4th gen; broader Gram-negative coverage including P. aeruginosa; better stability against AmpC beta-lactamases than 3rd gen
- Cefpirome - similar spectrum to cefepime
- Cefozopran - used in some countries for MDR Gram-negatives
Why 4th gen? They cross the outer membrane of Gram-negatives more efficiently and are more resistant to beta-lactamase hydrolysis than 3rd gen cephalosporins. - Goodman & Gilman, Antipseudomonal Cephalosporins
Ceftaroline Fosamil (listed as "Cefasoline fosamil" in notes)
A 5th generation cephalosporin (prodrug - converted to ceftaroline in vivo). Unique because it is the only beta-lactam active against MRSA - it binds PBP2a (the altered penicillin-binding protein that gives MRSA resistance). Available only as IV.
② Oxazolidinediones
Your notes list:
- Linezolid
- Tedizolid
These are oxazolidinone antibiotics (note: "oxazolidinediones" in your notes is likely "oxazolidinones"). They work by a unique mechanism - binding the 50S ribosomal subunit and preventing formation of the initiation complex, blocking protein synthesis at a step that other antibiotics do not target. This means no cross-resistance with other protein synthesis inhibitors.
| Drug | Spectrum | Key Use |
|---|---|---|
| Linezolid | Gram-positives (MRSA, VRE, VISA) | MRSA pneumonia, VRE infections |
| Tedizolid | Similar to linezolid, but more potent | Skin/soft tissue infections; fewer drug interactions |
Also listed:
- Glycylcyclines (tetracycline derivative): e.g., Tigecycline - broad-spectrum, active against MDR organisms including MRSA and VRE; used in hospital-acquired infections
- Lipopolysaccharides / Lipopeptides: likely referring to daptomycin class (though this appears in section ⑥ in your notes as lipoglycopeptides)
③ Tetracyclines (Glycylcyclines)
- Eravacycline - novel fluorocycline (next-gen tetracycline)
- Glycylcycline (Tigecycline) - active against MRSA, VRE, Acinetobacter; broad-spectrum; not active against P. aeruginosa
④ Aminoglycosides
Plazomicin
A next-generation aminoglycoside derived from sisomicin. Its key advantage: structural modifications prevent inactivation by most aminoglycoside-modifying enzymes (AMEs) that cause resistance to older aminoglycosides (gentamicin, tobramycin, amikacin). It is FDA-approved for complicated urinary tract infections caused by Enterobacteriaceae including CRE. - Goldman-Cecil Medicine, Aminoglycosides; Harrison's, Mechanisms of Resistance
⑤ Fluoroquinolones
Delafloxacin
A novel fluoroquinolone active against MRSA (unlike older fluoroquinolones). Has both IV and oral formulations. Used for acute bacterial skin infections and community-acquired bacterial pneumonia.
Moxifloxacin
Already clinically established, but grouped here as a "newer" fluoroquinolone. Excellent anaerobic and atypical coverage; used for respiratory infections and TB (as a second-line agent in MDR-TB regimens).
⑥ Lipoglycopeptides - Used in VRE infections
| Drug | Key Points |
|---|---|
| Telavancin | Active against MRSA, VISA, VRSA, some VRE; approved for skin infections and nosocomial pneumonia; causes QT prolongation and nephrotoxicity; interferes with coagulation tests (false elevation of PT) |
| Dalbavancin | Very long half-life (allows once-weekly or even single-dose dosing); approved for skin/soft tissue infections |
These are structurally related to vancomycin but with lipophilic side chains that anchor them to the bacterial membrane. They inhibit cell wall synthesis by binding D-Ala-D-Ala and also disrupt membrane integrity. - Harrison's Principles of Internal Medicine 22E, p. Glycopeptides and Lipoglycopeptides
A third agent in this class, oritavancin, may also have activity against some VRE strains.
⑦ Newer Antitubercular Drugs
These three agents are used for MDR-TB (multidrug-resistant) and XDR-TB (extensively drug-resistant tuberculosis):
| Drug | Class | Mechanism | Use |
|---|---|---|---|
| Bedaquiline | Diarylquinoline | Inhibits mycobacterial ATP synthase (F0 subunit) - unique mechanism, no cross-resistance | Core drug in MDR-TB and XDR-TB regimens; long t½ (~5.5 months); QT prolongation risk; metabolized by CYP3A4 |
| Pretomanid | Bicyclic nitroimidazopyran | (1) Inhibits mycolic acid synthesis under aerobic conditions; (2) generates reactive nitrogen species anaerobically (bactericidal against non-replicating TB) | FDA-approved for XDR-TB as part of BPaL regimen (Bedaquiline + Pretomanid + Linezolid) |
| Delamanid | Bicyclic nitroimidazopyran | Similar to pretomanid; inhibits mycolic acid synthesis | EMA-licensed for MDR-TB |
Bedaquiline kills both actively dividing and non-replicating (dormant/latent) mycobacteria - making it highly effective. - Goodman & Gilman's, Bicyclic Nitroimidazoles; Comprehensive Clinical Nephrology, Newer Drugs
Key "Big Picture" Summary
| Category | Problem Being Solved | Solution |
|---|---|---|
| Beta-lactam + inhibitor combos | Beta-lactamase destroys the antibiotic | Inhibit the enzyme to rescue the beta-lactam |
| 4th gen cephalosporins | AmpC and extended spectrum beta-lactamases | More enzyme-stable ring structure |
| Ceftaroline | MRSA (PBP2a) | Binds even the altered PBP |
| Oxazolidinones | MRSA, VRE | Completely novel ribosome target |
| Plazomicin | AME-mediated aminoglycoside resistance | Structural changes prevent enzyme recognition |
| Lipoglycopeptides | Vancomycin-resistant organisms | Dual mechanism; membrane disruption added |
| Bedaquiline/Pretomanid/Delamanid | MDR/XDR-TB | Novel mechanisms not shared with existing TB drugs |
This is a shared conversation. Sign in to Orris to start your own chat.